Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 5Phase 1 5Phase NA 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2Thoracic 1

Conditions

Neoplasm Metastasis 2Stomach Neoplasms 1Recurrence 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × PEGPH20 × Clear all
NCT02563548 2020-02-07

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Halozyme Therapeutics

Phase 1 Completed
56 enrolled 24 charts
Gastrointestinal

Stomach Neoplasms

NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Halozyme Therapeutics

Phase 1 Terminated
85 enrolled 17 charts
Gastrointestinal

Cholangiocarcinoma

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated
16 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01170897 2014-01-29

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Halozyme Therapeutics

Phase 1 Completed
27 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00834704 2013-03-26

PEG

Halozyme Therapeutics

Phase 1 Completed
14 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡